{"ticker": {"uuid": "604862f7-3d9a-467e-8afd-9810e40ea196", "symbol": "DRTS", "name": "Alpha Tau Medical Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT\u00ae in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-reports-positive-data-123000492.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T12:30:00+00:00", "published_display": "21 Jul 2026 12:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau rises on Alpha DaRT head and neck cancer data", "summary": "Alpha Tau Medical (DRTS) stock rose approximately 5% in premarket trading after releasing new data on its Alpha DaRT therapy combined with Merck's Keytruda. The combination demonstrated a 100% objective response rate in nine evaluable head and neck cancer patients. This positive ", "url": "https://seekingalpha.com/news/4615918-alpha-tau-rises-alpha-dart-head-and-neck-cancer-data", "source_name": "Seeking Alpha", "published_at": "2026-07-21T13:11:15", "published_display": "21 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau reports positive trial results for cancer therapy combo", "summary": "Alpha Tau Medical Ltd. announced positive results from a clinical study combining its Alpha DaRT therapy with pembrolizumab for elderly patients with head and neck squamous cell carcinoma. The study showed a 100% objective response rate and a median overall survival of 18.2 month", "url": "https://www.investing.com/news/company-news/alpha-tau-reports-positive-trial-results-for-cancer-therapy-combo-93CH-4803278", "source_name": "Investing.com", "published_at": "2026-07-21T13:11:15", "published_display": "21 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All 9 Evaluable Patients Responded in Alpha Tau Cancer Trial", "summary": "Alpha Tau (Nasdaq: DRTS) announced positive clinical trial results for its Alpha DaRT\u00ae therapy combined with pembrolizumab in elderly patients with advanced head and neck cancer, achieving a 100% objective response rate among all 9 evaluable patients. The study reported a median ", "url": "https://www.stocktitan.net/news/DRTS/alpha-tau-reports-positive-data-demonstrating-100-objective-response-1ghvs3kwt5a1.html", "source_name": "Stock Titan", "published_at": "2026-07-21T12:11:16", "published_display": "21 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "100% cancer response in Alpha DaRT trial for Alpha Tau Medical (Nasdaq: DRTS)", "summary": "Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT\u00ae therapy combined with pembrolizumab in elderly head and neck cancer patients, achieving a 100% objective response rate in nine evaluable patients. The study showed favorable median overall survival of 18.2", "url": "https://www.stocktitan.net/sec-filings/DRTS/6-k-alpha-tau-medical-ltd-current-report-foreign-issuer-fe447a27d811.html", "source_name": "Stock Titan", "published_at": "2026-07-21T12:11:15", "published_display": "21 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Reaches ADMIRE Milestone, Is The Stock Now Fully Valued?", "summary": "Alpha Tau Medical (DRTS) recently reported a significant milestone in its ADMIRE clinical study, successfully treating an immunocompromised patient with recurrent cutaneous squamous cell carcinoma using Alpha DaRT. This news has coincided with a substantial increase in its share ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-reaches-admire-milestone-is-the-stock", "source_name": "Simply Wall Street", "published_at": "2026-07-18T22:10:35", "published_display": "18 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment", "summary": "H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Alpha Tau Medical (NASDAQ:DRTS) after the successful treatment of the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in the ADMIRE study. This treatment utilized Alpha DaRT", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-alpha-tau-medical-stock-rating-on-immunocompromised-patient-treatment-93CH-4798281", "source_name": "Investing.com", "published_at": "2026-07-18T05:40:16", "published_display": "18 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Is Up 6.6% After First Immunocompromised cSCC Patient Treated With Alpha DaRT", "summary": "Alpha Tau Medical's stock rose 6.6% after successfully treating the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) using its Alpha DaRT therapy in the ADMIRE trial. This development expands the potential market for the Alpha DaRT platform ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-up-66-after-first-immunocompromise", "source_name": "Simply Wall Street", "published_at": "2026-07-18T05:40:16", "published_display": "18 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alpha Tau Medical Treats First Immunocompromised Patient in Alpha DaRT Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-medical-treats-first-134819466.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:48:19+00:00", "published_display": "15 Jul 2026 13:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-successfully-treats-first-123000207.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:30:00+00:00", "published_display": "15 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau's Trial Studies Skin Cancer in Immunocompromised Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQOVF4cExYNGU4dFdFMm1ZVklFMEJIc2F5MjFTV3JwSms3YXlMa2tUVnlsQnVIYWZsbUlmT0ZEbWhMaDBSWWhfQXBmZFA3emp1Wkd4WUkwVFBSNHpVYWZfeHVfZW9temwyMjdiUWxoSHpITkM1cUcxblVpTzQ1Q1pTZkg5SHdNNGQ5ZGxJX3Y0NzAwM0t5S0VZaWltTWo4THNDbWJPbDAxZFpEUEJ4aVBweEhsOUh6MFkzNTJRTWpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T12:30:00+00:00", "published_display": "15 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (Nasdaq: DRTS) treats first ADMIRE trial patient with Alpha DaRT", "summary": "Alpha Tau Medical (Nasdaq: DRTS) has announced the successful treatment of the first patient in its ADMIRE clinical trial. This study is evaluating the Alpha DaRT therapy for immunocompromised patients suffering from recurrent cutaneous squamous cell carcinoma (cSCC), a populatio", "url": "https://www.stocktitan.net/sec-filings/DRTS/6-k-alpha-tau-medical-ltd-current-report-foreign-issuer-bede0bd5a695.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:41:41", "published_display": "15 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alpha Tau Medical (DRTS) CFO trades 2,270 shares in exercise and sale", "summary": "Alpha Tau Medical's CFO, Levy Raphi, reported exercising 2,270 shares at $2.98 each and simultaneously selling the same number of shares in an open-market transaction at $14.0011 per share. Following these transactions, the CFO directly holds 90,180 Ordinary Shares. This activity", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-b1c9f38249d1.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:43:43", "published_display": "07 Jul 2026 11:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alpha Tau Medical Ltd. \u2013 NASDAQ:DRTS", "summary": "This article focuses on the enterprise value to revenue forward for Alpha Tau Medical Ltd. (NASDAQ: DRTS). It appears to be a financial data presentation rather than an analytical piece, originating from TradingView and referencing financial data providers like ICE Data Services ", "url": "https://www.tradingview.com/symbols/NASDAQ-DRTS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T07:43:43", "published_display": "07 Jul 2026 07:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Alpha Tau Medical Ltd. \u2013 BOATS:DRTS", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Alpha Tau Medical Ltd. (DRTS) on the BOATS platform. It highlights that no trades were recorded and presents the general financial overview section for the company. The content includes standard fin", "url": "https://www.tradingview.com/symbols/BOATS-DRTS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:43:43", "published_display": "07 Jul 2026 04:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Raphi Levy Sells Shares of Alpha Tau Medical Ltd (DRTS)", "summary": "Raphi Levy, CFO of Alpha Tau Medical Ltd's subsidiary, sold 17,873 shares of DRTS on July 2, 2026, reducing his holding to 90,180 shares. This transaction is part of a trend over the past year with no insider buys and six insider sells for Alpha Tau Medical Ltd. The company, focu", "url": "https://www.gurufocus.com/news/8945978/insider-sell-raphi-levy-sells-shares-of-alpha-tau-medical-ltd-drts", "source_name": "GuruFocus", "published_at": "2026-07-06T20:43:43", "published_display": "06 Jul 2026 20:43", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Alpha Tau Medical Ltd. \u2013 BOATS:DRTS", "summary": "The article focuses on the enterprise value to EBITDA forward of Alpha Tau Medical Ltd. (DRTS). It appears to be a financial data point or metric presented within the TradingView platform for this specific company. The content primarily lists navigation and footer elements rather", "url": "https://www.tradingview.com/symbols/BOATS-DRTS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T20:11:53", "published_display": "06 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Is Up 17.9% After First International Alpha DaRT Glioblastoma Procedure \u2013 Has The Bull Case Changed?", "summary": "Alpha Tau Medical's stockrose by 17.9% following the successful first international use of its Alpha DaRT technology for glioblastoma treatment in Jerusalem. While this expands the potential application of Alpha DaRT to hard-to-treat tumors, the article emphasizes that it does no", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-up-179-after-first-international-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T18:11:53", "published_display": "06 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) notice: 20,000 shares from option exercise to be sold", "summary": "Alpha Tau Medical Ltd. (DRTS) has filed a Form 144 notice for the proposed sale of 20,000 ordinary shares. These shares were acquired on July 6, 2026, through the exercise of employee stock options using cash payment. The filing also details multiple past sales by the same holder", "url": "https://www.stocktitan.net/sec-filings/DRTS/144-alpha-tau-medical-ltd-sec-filing-c304a92cc974.html", "source_name": "Stock Titan", "published_at": "2026-07-06T16:11:53", "published_display": "06 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) CFO exercises 17,873 options and sells 17,873 shares", "summary": "Alpha Tau Medical Ltd.'s CFO, Raphi Levy, engaged in an exercise-and-sell transaction on July 2, 2026. He exercised 17,873 Ordinary Shares at $2.98 each and simultaneously sold the same number of shares on the open market for an average price of $13.0027 per share. Following thes", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-0eda3cbcf662.html", "source_name": "Stock Titan", "published_at": "2026-07-06T15:11:53", "published_display": "06 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) price target increased by 15.15% to 9.69", "summary": "This article reports that the price target for Alpha Tau Medical (DRTS) has been increased by 15.15%, raising it to $9.69. No further details about the reasons for this increase or who made the adjustment are provided.", "url": "http://www.msn.com/en-us/money/topstocks/alpha-tau-medical-drts-price-target-increased-by-1515-to-969/ar-AA1ZzZOy?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-03T06:10:39", "published_display": "03 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (NASDAQ: DRTS) CFO sells 2,127 shares after exercising options", "summary": "Alpha Tau Medical's Chief Financial Officer, Raphi Levy, sold 2,127 Ordinary Shares in an open-market transaction at an average price of $13.0189 per share. This sale followed the exercise of options for the same number of shares at $2.98 each. After the transaction, Levy directl", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-03d35a4debf3.html", "source_name": "Stock Titan", "published_at": "2026-07-02T15:40:16", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Alpha Tau Medical Ltd. For: 2 July By Investing.com", "summary": "This article announces the filing of Form 144 for Alpha Tau Medical Ltd. on July 2. It's a short, informative piece from Investing.com, likely indicating an insider's intent to sell restricted stock. The piece includes market data for various indices, commodities, and stocks.", "url": "https://ca.investing.com/news/stock-market-news/form-144-alpha-tau-medical-ltd-for-2-july-93CH-4717952", "source_name": "Investing.com Canada", "published_at": "2026-07-02T10:40:16", "published_display": "02 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levy Raphi to sell 20,000 Alpha Tau shares (DRTS) via Form 144", "summary": "Levy Raphi has filed a Form 144 to sell 20,000 Ordinary Shares of Alpha Tau Medical Ltd. (DRTS), acquired through employee stock options. This proposed sale, scheduled for July 1, 2026, follows previous dispositions in June 2026 totaling 57,500 shares. The filing provides details", "url": "https://www.stocktitan.net/sec-filings/DRTS/144-alpha-tau-medical-ltd-sec-filing-e853eb2eba9f.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:39:04", "published_display": "02 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical Ltd. Warrant 2022-07.03.27 on Alpha Tau Med Rg-A Financial Disclosures & SEC Filings", "summary": "This article provides a compilation of financial disclosures and SEC filings for Alpha Tau Medical Ltd. (DRTSW) from 2024 to 2026. It highlights key events such as investor conferences, earnings releases, clinical trial advancements, regulatory milestones, and various financial u", "url": "https://www.tradingview.com/symbols/BOATS-DRTSW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T08:39:04", "published_display": "02 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Raphi Levy Sells 20,000 Shares of Alpha Tau Medica", "summary": "Raphi Levy, CFO of Alpha Tau Medical Ltd's subsidiary, sold 20,000 shares of Alpha Tau Medical Ltd (DRTS) on June 30, 2026, reducing his holding to 90,180 shares. This transaction is part of a trend for Levy, who has sold a total of 90,000 shares over the past year with no purcha", "url": "https://www.gurufocus.com/news/8941061/insider-sell-raphi-levy-sells-20000-shares-of-alpha-tau-medical-ltd-drts", "source_name": "GuruFocus", "published_at": "2026-07-01T15:10:02", "published_display": "01 Jul 2026 15:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) CFO sells 20,000 shares, retains 90,180", "summary": "Alpha Tau Medical's Chief Financial Officer, Levy Raphi, sold 20,000 Ordinary Shares in an open-market transaction at an average price of $12.0022 per share. Following this sale, Raphi still directly holds 90,180 Ordinary Shares, indicating a retained significant equity exposure.", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-cfb03997c09c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:10:02", "published_display": "01 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sells 37,500 shares at Alpha Tau Medical (NASDAQ: DRTS)", "summary": "An insider at Alpha Tau Medical (NASDAQ: DRTS) has sold a total of 37,500 ordinary shares through two transactions in June 2026, generating proceeds of $167,051.00 and $220,004.00 respectively. These sales were reported via a Form 144 filing, which also noted a prior issuance of ", "url": "https://www.stocktitan.net/sec-filings/DRTS/144-alpha-tau-medical-ltd-sec-filing-f6a70bd6a9e9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T15:40:55", "published_display": "30 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical stock hits 52-week high at $11.64", "summary": "Alpha Tau Medical (DRTS) stock reached a 52-week high of $11.64, reflecting a significant 266.03% year-on-year increase and bringing its market capitalization to approximately $1.04 billion. Despite this surge, InvestingPro data suggests the stock might be overvalued. Recent deve", "url": "https://www.investing.com/news/company-news/alpha-tau-medical-stock-hits-52week-high-at-1164-93CH-4768103", "source_name": "Investing.com", "published_at": "2026-06-30T13:40:55", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Alpha Tau Medical (DRTS) Is Up 11.2% After First Alpha DaRT Brain-Tumor Procedure News", "summary": "Alpha Tau Medical (DRTS) saw an 11.2% stock price increase following the successful first international Alpha DaRT treatment of a glioblastoma patient in Israel. This procedure, which used Alpha DaRT\u2019s brain-specific delivery system, marks a significant milestone and extends the ", "url": "https://www.sahmcapital.com/news/content/why-alpha-tau-medical-drts-is-up-112-after-first-alpha-dart-brain-tumor-procedure-news-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-28T22:40:55", "published_display": "28 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical\u2019s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-medical-drts-first-190613585.html", "source_name": "Simply Wall St.", "published_at": "2026-06-27T19:06:13+00:00", "published_display": "27 Jun 2026 19:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Looks Fully Priced After Its Glioblastoma Treatment Milestone", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raphi Levy sale: 17,500 shares disclosed for Alpha Tau Medical (DRTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPZC1IcktSX2xTbHhGTUw2WHFQRVZsaG9RNlprdlg5OEJDdk1MaC1CSWZRNXJlWnZWb3VjLWppVFR6ZXZLc3dCY19GVHd3eGZYUVdoVmcteXRoWjFLMGEzQkpIS0JYRmdxVllydEpJMVhmSjFJbG84RDdRMmVfd2hLdmdKSGFYcEt0SjJZV0ExVzFvM0xFaWlibWF3OXE0SzQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) CFO reports open-market sale of 17,500 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdXNGUGlnVEFBZ0VWRmpST1huVUJVeEhNcmVBVzJnTmlGd2h0eThUZ1YzczB4anpjQlJVMVJiZmxWRHUwNTAxeDEybU0zZTRKa1NkWklZUDRtelBmSERsWmpBWkRuelRVMVJFWS04NDBWQi1aV0NEVFU2VDFFTjN4Y1JSQTNtMWNhWDVRRHZUaG0xUG1hTXExWGU5S1FESnBHT1FzNldJYWwzWkx2REI2TW5rODVLdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed\u2019s portfolio swells: Alpha Tau stake up $128M, Scilex loan repaid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbXJSSnI4UXYzVXYwNW44SFlScTBHVXZ0RC04UjBJVmd4MlJGUk9hYVQybUlOakR6bmlWbl9CbENVTVRJVTViZnRvanhzWHVZTDd6TEtVTHZteDJTa29HQmw5SjBYcmtrcE9qVmUyS24xRFlSa202WEVpekNRaGlzVnZQU3NHdG9SZXVtNU81WGlELTdsWlY5aVVDb0hJMVVWRHR4LTVaU2xuXzg0RGJVZ0c2a1dmUG85eW5Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT\u00ae at Hadassah University Medical Center in Israel", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-successfully-treats-first-123000964.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:30:00+00:00", "published_display": "23 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau first treats glioblastoma patient outside the U.S. in Israel", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYlhmTHFWMWMtQkVCN1l1N1lJU2FlRnVwVXg0bEZPWkQ2ZlhZT0lISHZXenlNTW9Ib29Nc1NnUVFCVy13UE9yNmROZVdMNjcyc1kxTmNka0NHbERDajVJa0Zmbng4R2gyV0F4YnZYZjJid1lDS1lKckNKV1N2Q25saVcyMEpvdm0zdXVQRWV2Z1RQc0lmNVBzQmFJLUZjT3o2MWladi16WDF5NTRhbHdJUDJaX19RYnMwMGtQY25R?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA trial clearance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSGxNREV0Y2ExVVNYSTd1NFZsbDhlUS1jVUZXZ2V0T3hyMVcxQkRUb09NcHJNbHhSdUVUbXVKeDRrV1duMGRQNXdicmNkUGFYQkJyRlRLWVNkLXExYWNOdGc3cHhqckg2OVpqYlVOMmFlZkdvTC1LV043bEtVUjZtVjJUbkl2RGlLV3VwZFNCWGgtSGpfYzNIdG4wclVJeHI1bHBEeFZ4cmMwZnZHVWlyMjV1aE9jNkh5blFPQlk1dWEwTVlVNk9CeUU1OWJoS1dGd1Z0dQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical: A Lot Of Shots On Goal (NASDAQ:DRTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZy14S0tuRzZwTnFRS0UwRGhQVlZKRkMteDlFcU9XUy00NHFodERsdHJsZnh5NVJXTmJ5V01maWJYeThsa25TZ3V3eS05ZHRKV0t2WTljSVBaNmlsZGw0ZThYZHVsZG9XbW5sX29PenhsQnVfOXNoQzNmYmI1WHhQQVoyWlhBOEVo?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-tau-medical-says-fda-130235970.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:02:35+00:00", "published_display": "11 Jun 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-tau-receives-fda-clearance-123000174.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:30:00+00:00", "published_display": "11 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brain cancer trial sees 100% local control as FDA lets Alpha Tau treat patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQemV3a0FLdE4zMGF0M0htWTZTSnRWSTJQaTdxZ2ZfamlkdkdfYWctZVZFOUtKWENPZnVwcTFjck41Ny1rNE5FMERIdzduNURLZmFsUkt3OHVpaUQxeTFEYnFNZ2U2UWZuNFJ2bGFzcnlwVnkzaTl4LXdZbTFwbDZEUV9yak9Qd3EwLVMxNzNXM2xYR1JRbTZVVmMwTHFwZ2J0TVNjQzhkem1kNW94b1h6THVzUWRDY3BWNloyeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New prostate cancer radiation option backed by $35M Alpha Tau\u2013Tolmar deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUWpzVDVYNHNXVnRJQWd4dTVoSS1oOW9IdURkNlhENHpwMGtrOHc5VUlDLUdJX2FFODdHbmdsYi1EdG9VQmhqdlZ0OVo0eTh5RjhhWDhzVW5aZ1FsRm9vSDRINUF0Q2ZZTTJDeHpPY3JDQi14YWZ6MFNyNFpzZWxMVjdJLWY2bjVrcEg0bERPRV9jZm0teFJfbVI5UkZWQnphRlRsRU45MWpndl9kZUYwZHFfUUxGYUFSZWZQaC1VdHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brain cancer trial reports 100% local control in first Alpha Tau patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNRW5TZ18xZWZqLWJmSE1qQzlPOFNGeU9hMkh3R0Z0S0NFMHluQXlDdnNsRlpINUgzVFRMb2Q1RzdFN25Od3E3ZzJuYmw3Rkt3d3pYTlJiVjN1NEROdzdpaGdVbVBZSzJuSDlSb3JndEtOdWF1RlZrZW52RTk3UVRtSElkcTdoNmFGSGNiMXd0ZVBQcmh0aHM4bnRieUJIZUk2ZlpISDhfcGNqUHdfdWthQ0ZMRk4tUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright raises Alpha Tau Medical stock price target to $15 on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNWGY1UjVoa3MtUzl4WHhrQWtrMW41aW1VMExUOEI0U1RaamYxUVVyaFZsbUJCR2ZHNWNBVU5ad3pqUFlBUkZNaFpiS052S0VuUlZiOFd0Mk9weVlIaU9GS0p0MVJlRGIxNmFYamFIT2lnSW5RSVRsYWpoRWJaR1dTenhFbWJkeXdjY3pnOHlmbUVGWWp6U1VkMjR5eHgxN2hxNll2NE5WYTZ2cnZJbHBXVW5Zby03aGNWaG1kM2RPMUFmeEx2MHFyeElDSm9FLTd1OGNF?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deadly brain cancer: all tumors controlled in 3-patient Alpha Tau trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNajhIVWhWbWpucENVVzFGMnpmQlF0OTlFSjU0YWFWR0xQXzY1dzgya2ZiQkxDRTNyOXhkNENxcndLQzlsTEVsQ2E3a2d1U3BvbTQxS0ZQVEJ5TmpOZVdlcTZyWXVmRkpfZFQ0eUY3aDc2ck43aWdfU2NSamMxZ1BQYTN1QUY3YlJuM3RuRDdEVkdBRzVQNEw5NW9UNVVjRG9pLTM0MWdyVXhBSUpMU3ljMllUQl83b21rZVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxONFdRWVc1UFBfejdUNGdZN191QXh4UV9pWnZjelJhcWlOR29iWDFiVDRra0p1OTVqWktXV3Z0VkNOMjFBX25HbkhjQzJvTnZxczg5VmdBdWtvQ1RGTzMyQXlOZU1mWVctNGlRenRkTFg0R0xVNktiVXVQZEhKRF9OSDFwV1d6dEpTVElzNGhIZGRXcmZ4NDV0UlE5VnNBSFRJOHc5R2pzUkRRNHQwS2xFQkZRVUIxeGpRdG91cmhQSQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT\u00ae in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-reports-positive-data-123000492.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T12:30:00+00:00", "published_display": "21 Jul 2026 12:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau rises on Alpha DaRT head and neck cancer data", "summary": "Alpha Tau Medical (DRTS) stock rose approximately 5% in premarket trading after releasing new data on its Alpha DaRT therapy combined with Merck's Keytruda. The combination demonstrated a 100% objective response rate in nine evaluable head and neck cancer patients. This positive ", "url": "https://seekingalpha.com/news/4615918-alpha-tau-rises-alpha-dart-head-and-neck-cancer-data", "source_name": "Seeking Alpha", "published_at": "2026-07-21T13:11:15", "published_display": "21 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau reports positive trial results for cancer therapy combo", "summary": "Alpha Tau Medical Ltd. announced positive results from a clinical study combining its Alpha DaRT therapy with pembrolizumab for elderly patients with head and neck squamous cell carcinoma. The study showed a 100% objective response rate and a median overall survival of 18.2 month", "url": "https://www.investing.com/news/company-news/alpha-tau-reports-positive-trial-results-for-cancer-therapy-combo-93CH-4803278", "source_name": "Investing.com", "published_at": "2026-07-21T13:11:15", "published_display": "21 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All 9 Evaluable Patients Responded in Alpha Tau Cancer Trial", "summary": "Alpha Tau (Nasdaq: DRTS) announced positive clinical trial results for its Alpha DaRT\u00ae therapy combined with pembrolizumab in elderly patients with advanced head and neck cancer, achieving a 100% objective response rate among all 9 evaluable patients. The study reported a median ", "url": "https://www.stocktitan.net/news/DRTS/alpha-tau-reports-positive-data-demonstrating-100-objective-response-1ghvs3kwt5a1.html", "source_name": "Stock Titan", "published_at": "2026-07-21T12:11:16", "published_display": "21 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "100% cancer response in Alpha DaRT trial for Alpha Tau Medical (Nasdaq: DRTS)", "summary": "Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT\u00ae therapy combined with pembrolizumab in elderly head and neck cancer patients, achieving a 100% objective response rate in nine evaluable patients. The study showed favorable median overall survival of 18.2", "url": "https://www.stocktitan.net/sec-filings/DRTS/6-k-alpha-tau-medical-ltd-current-report-foreign-issuer-fe447a27d811.html", "source_name": "Stock Titan", "published_at": "2026-07-21T12:11:15", "published_display": "21 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Reaches ADMIRE Milestone, Is The Stock Now Fully Valued?", "summary": "Alpha Tau Medical (DRTS) recently reported a significant milestone in its ADMIRE clinical study, successfully treating an immunocompromised patient with recurrent cutaneous squamous cell carcinoma using Alpha DaRT. This news has coincided with a substantial increase in its share ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-reaches-admire-milestone-is-the-stock", "source_name": "Simply Wall Street", "published_at": "2026-07-18T22:10:35", "published_display": "18 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment", "summary": "H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Alpha Tau Medical (NASDAQ:DRTS) after the successful treatment of the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in the ADMIRE study. This treatment utilized Alpha DaRT", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-alpha-tau-medical-stock-rating-on-immunocompromised-patient-treatment-93CH-4798281", "source_name": "Investing.com", "published_at": "2026-07-18T05:40:16", "published_display": "18 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Is Up 6.6% After First Immunocompromised cSCC Patient Treated With Alpha DaRT", "summary": "Alpha Tau Medical's stock rose 6.6% after successfully treating the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) using its Alpha DaRT therapy in the ADMIRE trial. This development expands the potential market for the Alpha DaRT platform ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-up-66-after-first-immunocompromise", "source_name": "Simply Wall Street", "published_at": "2026-07-18T05:40:16", "published_display": "18 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical Treats First Immunocompromised Patient in Alpha DaRT Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-medical-treats-first-134819466.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:48:19+00:00", "published_display": "15 Jul 2026 13:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-successfully-treats-first-123000207.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:30:00+00:00", "published_display": "15 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau's Trial Studies Skin Cancer in Immunocompromised Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQOVF4cExYNGU4dFdFMm1ZVklFMEJIc2F5MjFTV3JwSms3YXlMa2tUVnlsQnVIYWZsbUlmT0ZEbWhMaDBSWWhfQXBmZFA3emp1Wkd4WUkwVFBSNHpVYWZfeHVfZW9temwyMjdiUWxoSHpITkM1cUcxblVpTzQ1Q1pTZkg5SHdNNGQ5ZGxJX3Y0NzAwM0t5S0VZaWltTWo4THNDbWJPbDAxZFpEUEJ4aVBweEhsOUh6MFkzNTJRTWpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T12:30:00+00:00", "published_display": "15 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (Nasdaq: DRTS) treats first ADMIRE trial patient with Alpha DaRT", "summary": "Alpha Tau Medical (Nasdaq: DRTS) has announced the successful treatment of the first patient in its ADMIRE clinical trial. This study is evaluating the Alpha DaRT therapy for immunocompromised patients suffering from recurrent cutaneous squamous cell carcinoma (cSCC), a populatio", "url": "https://www.stocktitan.net/sec-filings/DRTS/6-k-alpha-tau-medical-ltd-current-report-foreign-issuer-bede0bd5a695.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:41:41", "published_display": "15 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) CFO trades 2,270 shares in exercise and sale", "summary": "Alpha Tau Medical's CFO, Levy Raphi, reported exercising 2,270 shares at $2.98 each and simultaneously selling the same number of shares in an open-market transaction at $14.0011 per share. Following these transactions, the CFO directly holds 90,180 Ordinary Shares. This activity", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-b1c9f38249d1.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:43:43", "published_display": "07 Jul 2026 11:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alpha Tau Medical Ltd. \u2013 NASDAQ:DRTS", "summary": "This article focuses on the enterprise value to revenue forward for Alpha Tau Medical Ltd. (NASDAQ: DRTS). It appears to be a financial data presentation rather than an analytical piece, originating from TradingView and referencing financial data providers like ICE Data Services ", "url": "https://www.tradingview.com/symbols/NASDAQ-DRTS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T07:43:43", "published_display": "07 Jul 2026 07:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Alpha Tau Medical Ltd. \u2013 BOATS:DRTS", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Alpha Tau Medical Ltd. (DRTS) on the BOATS platform. It highlights that no trades were recorded and presents the general financial overview section for the company. The content includes standard fin", "url": "https://www.tradingview.com/symbols/BOATS-DRTS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:43:43", "published_display": "07 Jul 2026 04:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Raphi Levy Sells Shares of Alpha Tau Medical Ltd (DRTS)", "summary": "Raphi Levy, CFO of Alpha Tau Medical Ltd's subsidiary, sold 17,873 shares of DRTS on July 2, 2026, reducing his holding to 90,180 shares. This transaction is part of a trend over the past year with no insider buys and six insider sells for Alpha Tau Medical Ltd. The company, focu", "url": "https://www.gurufocus.com/news/8945978/insider-sell-raphi-levy-sells-shares-of-alpha-tau-medical-ltd-drts", "source_name": "GuruFocus", "published_at": "2026-07-06T20:43:43", "published_display": "06 Jul 2026 20:43", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Alpha Tau Medical Ltd. \u2013 BOATS:DRTS", "summary": "The article focuses on the enterprise value to EBITDA forward of Alpha Tau Medical Ltd. (DRTS). It appears to be a financial data point or metric presented within the TradingView platform for this specific company. The content primarily lists navigation and footer elements rather", "url": "https://www.tradingview.com/symbols/BOATS-DRTS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T20:11:53", "published_display": "06 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Is Up 17.9% After First International Alpha DaRT Glioblastoma Procedure \u2013 Has The Bull Case Changed?", "summary": "Alpha Tau Medical's stockrose by 17.9% following the successful first international use of its Alpha DaRT technology for glioblastoma treatment in Jerusalem. While this expands the potential application of Alpha DaRT to hard-to-treat tumors, the article emphasizes that it does no", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-up-179-after-first-international-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T18:11:53", "published_display": "06 Jul 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) notice: 20,000 shares from option exercise to be sold", "summary": "Alpha Tau Medical Ltd. (DRTS) has filed a Form 144 notice for the proposed sale of 20,000 ordinary shares. These shares were acquired on July 6, 2026, through the exercise of employee stock options using cash payment. The filing also details multiple past sales by the same holder", "url": "https://www.stocktitan.net/sec-filings/DRTS/144-alpha-tau-medical-ltd-sec-filing-c304a92cc974.html", "source_name": "Stock Titan", "published_at": "2026-07-06T16:11:53", "published_display": "06 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) CFO exercises 17,873 options and sells 17,873 shares", "summary": "Alpha Tau Medical Ltd.'s CFO, Raphi Levy, engaged in an exercise-and-sell transaction on July 2, 2026. He exercised 17,873 Ordinary Shares at $2.98 each and simultaneously sold the same number of shares on the open market for an average price of $13.0027 per share. Following thes", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-0eda3cbcf662.html", "source_name": "Stock Titan", "published_at": "2026-07-06T15:11:53", "published_display": "06 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) price target increased by 15.15% to 9.69", "summary": "This article reports that the price target for Alpha Tau Medical (DRTS) has been increased by 15.15%, raising it to $9.69. No further details about the reasons for this increase or who made the adjustment are provided.", "url": "http://www.msn.com/en-us/money/topstocks/alpha-tau-medical-drts-price-target-increased-by-1515-to-969/ar-AA1ZzZOy?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-03T06:10:39", "published_display": "03 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (NASDAQ: DRTS) CFO sells 2,127 shares after exercising options", "summary": "Alpha Tau Medical's Chief Financial Officer, Raphi Levy, sold 2,127 Ordinary Shares in an open-market transaction at an average price of $13.0189 per share. This sale followed the exercise of options for the same number of shares at $2.98 each. After the transaction, Levy directl", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-03d35a4debf3.html", "source_name": "Stock Titan", "published_at": "2026-07-02T15:40:16", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Alpha Tau Medical Ltd. For: 2 July By Investing.com", "summary": "This article announces the filing of Form 144 for Alpha Tau Medical Ltd. on July 2. It's a short, informative piece from Investing.com, likely indicating an insider's intent to sell restricted stock. The piece includes market data for various indices, commodities, and stocks.", "url": "https://ca.investing.com/news/stock-market-news/form-144-alpha-tau-medical-ltd-for-2-july-93CH-4717952", "source_name": "Investing.com Canada", "published_at": "2026-07-02T10:40:16", "published_display": "02 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levy Raphi to sell 20,000 Alpha Tau shares (DRTS) via Form 144", "summary": "Levy Raphi has filed a Form 144 to sell 20,000 Ordinary Shares of Alpha Tau Medical Ltd. (DRTS), acquired through employee stock options. This proposed sale, scheduled for July 1, 2026, follows previous dispositions in June 2026 totaling 57,500 shares. The filing provides details", "url": "https://www.stocktitan.net/sec-filings/DRTS/144-alpha-tau-medical-ltd-sec-filing-e853eb2eba9f.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:39:04", "published_display": "02 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical Ltd. Warrant 2022-07.03.27 on Alpha Tau Med Rg-A Financial Disclosures & SEC Filings", "summary": "This article provides a compilation of financial disclosures and SEC filings for Alpha Tau Medical Ltd. (DRTSW) from 2024 to 2026. It highlights key events such as investor conferences, earnings releases, clinical trial advancements, regulatory milestones, and various financial u", "url": "https://www.tradingview.com/symbols/BOATS-DRTSW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T08:39:04", "published_display": "02 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Raphi Levy Sells 20,000 Shares of Alpha Tau Medica", "summary": "Raphi Levy, CFO of Alpha Tau Medical Ltd's subsidiary, sold 20,000 shares of Alpha Tau Medical Ltd (DRTS) on June 30, 2026, reducing his holding to 90,180 shares. This transaction is part of a trend for Levy, who has sold a total of 90,000 shares over the past year with no purcha", "url": "https://www.gurufocus.com/news/8941061/insider-sell-raphi-levy-sells-20000-shares-of-alpha-tau-medical-ltd-drts", "source_name": "GuruFocus", "published_at": "2026-07-01T15:10:02", "published_display": "01 Jul 2026 15:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) CFO sells 20,000 shares, retains 90,180", "summary": "Alpha Tau Medical's Chief Financial Officer, Levy Raphi, sold 20,000 Ordinary Shares in an open-market transaction at an average price of $12.0022 per share. Following this sale, Raphi still directly holds 90,180 Ordinary Shares, indicating a retained significant equity exposure.", "url": "https://www.stocktitan.net/sec-filings/DRTS/form-4-alpha-tau-medical-ltd-insider-trading-activity-cfb03997c09c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:10:02", "published_display": "01 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sells 37,500 shares at Alpha Tau Medical (NASDAQ: DRTS)", "summary": "An insider at Alpha Tau Medical (NASDAQ: DRTS) has sold a total of 37,500 ordinary shares through two transactions in June 2026, generating proceeds of $167,051.00 and $220,004.00 respectively. These sales were reported via a Form 144 filing, which also noted a prior issuance of ", "url": "https://www.stocktitan.net/sec-filings/DRTS/144-alpha-tau-medical-ltd-sec-filing-f6a70bd6a9e9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T15:40:55", "published_display": "30 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical stock hits 52-week high at $11.64", "summary": "Alpha Tau Medical (DRTS) stock reached a 52-week high of $11.64, reflecting a significant 266.03% year-on-year increase and bringing its market capitalization to approximately $1.04 billion. Despite this surge, InvestingPro data suggests the stock might be overvalued. Recent deve", "url": "https://www.investing.com/news/company-news/alpha-tau-medical-stock-hits-52week-high-at-1164-93CH-4768103", "source_name": "Investing.com", "published_at": "2026-06-30T13:40:55", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Alpha Tau Medical (DRTS) Is Up 11.2% After First Alpha DaRT Brain-Tumor Procedure News", "summary": "Alpha Tau Medical (DRTS) saw an 11.2% stock price increase following the successful first international Alpha DaRT treatment of a glioblastoma patient in Israel. This procedure, which used Alpha DaRT\u2019s brain-specific delivery system, marks a significant milestone and extends the ", "url": "https://www.sahmcapital.com/news/content/why-alpha-tau-medical-drts-is-up-112-after-first-alpha-dart-brain-tumor-procedure-news-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-28T22:40:55", "published_display": "28 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical\u2019s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-medical-drts-first-190613585.html", "source_name": "Simply Wall St.", "published_at": "2026-06-27T19:06:13+00:00", "published_display": "27 Jun 2026 19:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) Looks Fully Priced After Its Glioblastoma Treatment Milestone", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raphi Levy sale: 17,500 shares disclosed for Alpha Tau Medical (DRTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPZC1IcktSX2xTbHhGTUw2WHFQRVZsaG9RNlprdlg5OEJDdk1MaC1CSWZRNXJlWnZWb3VjLWppVFR6ZXZLc3dCY19GVHd3eGZYUVdoVmcteXRoWjFLMGEzQkpIS0JYRmdxVllydEpJMVhmSjFJbG84RDdRMmVfd2hLdmdKSGFYcEt0SjJZV0ExVzFvM0xFaWlibWF3OXE0SzQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical (DRTS) CFO reports open-market sale of 17,500 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdXNGUGlnVEFBZ0VWRmpST1huVUJVeEhNcmVBVzJnTmlGd2h0eThUZ1YzczB4anpjQlJVMVJiZmxWRHUwNTAxeDEybU0zZTRKa1NkWklZUDRtelBmSERsWmpBWkRuelRVMVJFWS04NDBWQi1aV0NEVFU2VDFFTjN4Y1JSQTNtMWNhWDVRRHZUaG0xUG1hTXExWGU5S1FESnBHT1FzNldJYWwzWkx2REI2TW5rODVLdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed\u2019s portfolio swells: Alpha Tau stake up $128M, Scilex loan repaid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbXJSSnI4UXYzVXYwNW44SFlScTBHVXZ0RC04UjBJVmd4MlJGUk9hYVQybUlOakR6bmlWbl9CbENVTVRJVTViZnRvanhzWHVZTDd6TEtVTHZteDJTa29HQmw5SjBYcmtrcE9qVmUyS24xRFlSa202WEVpekNRaGlzVnZQU3NHdG9SZXVtNU81WGlELTdsWlY5aVVDb0hJMVVWRHR4LTVaU2xuXzg0RGJVZ0c2a1dmUG85eW5Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT\u00ae at Hadassah University Medical Center in Israel", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-tau-successfully-treats-first-123000964.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:30:00+00:00", "published_display": "23 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau first treats glioblastoma patient outside the U.S. in Israel", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYlhmTHFWMWMtQkVCN1l1N1lJU2FlRnVwVXg0bEZPWkQ2ZlhZT0lISHZXenlNTW9Ib29Nc1NnUVFCVy13UE9yNmROZVdMNjcyc1kxTmNka0NHbERDajVJa0Zmbng4R2gyV0F4YnZYZjJid1lDS1lKckNKV1N2Q25saVcyMEpvdm0zdXVQRWV2Z1RQc0lmNVBzQmFJLUZjT3o2MWladi16WDF5NTRhbHdJUDJaX19RYnMwMGtQY25R?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA trial clearance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSGxNREV0Y2ExVVNYSTd1NFZsbDhlUS1jVUZXZ2V0T3hyMVcxQkRUb09NcHJNbHhSdUVUbXVKeDRrV1duMGRQNXdicmNkUGFYQkJyRlRLWVNkLXExYWNOdGc3cHhqckg2OVpqYlVOMmFlZkdvTC1LV043bEtVUjZtVjJUbkl2RGlLV3VwZFNCWGgtSGpfYzNIdG4wclVJeHI1bHBEeFZ4cmMwZnZHVWlyMjV1aE9jNkh5blFPQlk1dWEwTVlVNk9CeUU1OWJoS1dGd1Z0dQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical: A Lot Of Shots On Goal (NASDAQ:DRTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZy14S0tuRzZwTnFRS0UwRGhQVlZKRkMteDlFcU9XUy00NHFodERsdHJsZnh5NVJXTmJ5V01maWJYeThsa25TZ3V3eS05ZHRKV0t2WTljSVBaNmlsZGw0ZThYZHVsZG9XbW5sX29PenhsQnVfOXNoQzNmYmI1WHhQQVoyWlhBOEVo?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-tau-medical-says-fda-130235970.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:02:35+00:00", "published_display": "11 Jun 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-tau-receives-fda-clearance-123000174.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:30:00+00:00", "published_display": "11 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brain cancer trial sees 100% local control as FDA lets Alpha Tau treat patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQemV3a0FLdE4zMGF0M0htWTZTSnRWSTJQaTdxZ2ZfamlkdkdfYWctZVZFOUtKWENPZnVwcTFjck41Ny1rNE5FMERIdzduNURLZmFsUkt3OHVpaUQxeTFEYnFNZ2U2UWZuNFJ2bGFzcnlwVnkzaTl4LXdZbTFwbDZEUV9yak9Qd3EwLVMxNzNXM2xYR1JRbTZVVmMwTHFwZ2J0TVNjQzhkem1kNW94b1h6THVzUWRDY3BWNloyeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New prostate cancer radiation option backed by $35M Alpha Tau\u2013Tolmar deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUWpzVDVYNHNXVnRJQWd4dTVoSS1oOW9IdURkNlhENHpwMGtrOHc5VUlDLUdJX2FFODdHbmdsYi1EdG9VQmhqdlZ0OVo0eTh5RjhhWDhzVW5aZ1FsRm9vSDRINUF0Q2ZZTTJDeHpPY3JDQi14YWZ6MFNyNFpzZWxMVjdJLWY2bjVrcEg0bERPRV9jZm0teFJfbVI5UkZWQnphRlRsRU45MWpndl9kZUYwZHFfUUxGYUFSZWZQaC1VdHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brain cancer trial reports 100% local control in first Alpha Tau patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNRW5TZ18xZWZqLWJmSE1qQzlPOFNGeU9hMkh3R0Z0S0NFMHluQXlDdnNsRlpINUgzVFRMb2Q1RzdFN25Od3E3ZzJuYmw3Rkt3d3pYTlJiVjN1NEROdzdpaGdVbVBZSzJuSDlSb3JndEtOdWF1RlZrZW52RTk3UVRtSElkcTdoNmFGSGNiMXd0ZVBQcmh0aHM4bnRieUJIZUk2ZlpISDhfcGNqUHdfdWthQ0ZMRk4tUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Alpha Tau Medical stock price target to $15 on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNWGY1UjVoa3MtUzl4WHhrQWtrMW41aW1VMExUOEI0U1RaamYxUVVyaFZsbUJCR2ZHNWNBVU5ad3pqUFlBUkZNaFpiS052S0VuUlZiOFd0Mk9weVlIaU9GS0p0MVJlRGIxNmFYamFIT2lnSW5RSVRsYWpoRWJaR1dTenhFbWJkeXdjY3pnOHlmbUVGWWp6U1VkMjR5eHgxN2hxNll2NE5WYTZ2cnZJbHBXVW5Zby03aGNWaG1kM2RPMUFmeEx2MHFyeElDSm9FLTd1OGNF?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deadly brain cancer: all tumors controlled in 3-patient Alpha Tau trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNajhIVWhWbWpucENVVzFGMnpmQlF0OTlFSjU0YWFWR0xQXzY1dzgya2ZiQkxDRTNyOXhkNENxcndLQzlsTEVsQ2E3a2d1U3BvbTQxS0ZQVEJ5TmpOZVdlcTZyWXVmRkpfZFQ0eUY3aDc2ck43aWdfU2NSamMxZ1BQYTN1QUY3YlJuM3RuRDdEVkdBRzVQNEw5NW9UNVVjRG9pLTM0MWdyVXhBSUpMU3ljMllUQl83b21rZVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxONFdRWVc1UFBfejdUNGdZN191QXh4UV9pWnZjelJhcWlOR29iWDFiVDRra0p1OTVqWktXV3Z0VkNOMjFBX25HbkhjQzJvTnZxczg5VmdBdWtvQ1RGTzMyQXlOZU1mWVctNGlRenRkTFg0R0xVNktiVXVQZEhKRF9OSDFwV1d6dEpTVElzNGhIZGRXcmZ4NDV0UlE5VnNBSFRJOHc5R2pzUkRRNHQwS2xFQkZRVUIxeGpRdG91cmhQSQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 56, "sentiment_summary": {"positive": 13, "negative": 4, "neutral": 39, "score": 54, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 19.4, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 13.55, "latest_week": "2026-07-17", "one_week_move": 6.6, "four_week_move": 38.5, "twelve_week_move": 67.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.537373, "market_dynamics_buy_signal": false, "relative_strength": 92.601234, "fair_value_gap": 232.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.3159, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.6% over one week, +38.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 19}, {"label": "Market source", "count": 6}, {"label": "Investing.com", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.6% over one week, +38.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT\u00ae in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success"}], "updated_at": "2026-07-22T01:01:11.342700+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}